Last reviewed · How we verify

Arm B: FOLFIRI or FOLFOX — Competitive Intelligence Brief

Arm B: FOLFIRI or FOLFOX (Arm B: FOLFIRI or FOLFOX) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy regimen. Area: Oncology.

phase 3 Combination chemotherapy regimen DNA (topoisomerase I for irinotecan; DNA cross-linking for oxaliplatin; thymidylate synthase for 5-FU) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Arm B: FOLFIRI or FOLFOX (Arm B: FOLFIRI or FOLFOX) — Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS. FOLFIRI and FOLFOX are combination chemotherapy regimens that inhibit DNA synthesis and cell division through fluorouracil-based cytotoxic activity, with irinotecan targeting topoisomerase I or oxaliplatin targeting DNA cross-linking.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Arm B: FOLFIRI or FOLFOX TARGET Arm B: FOLFIRI or FOLFOX Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS phase 3 Combination chemotherapy regimen DNA (topoisomerase I for irinotecan; DNA cross-linking for oxaliplatin; thymidylate synthase for 5-FU)
CEV chemotherapy CEV chemotherapy Sun Yat-sen University marketed Combination chemotherapy regimen
FEC FEC Hoffmann-La Roche marketed Combination chemotherapy regimen
Consolidation Chemotherapy Consolidation Chemotherapy National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos marketed Combination chemotherapy regimen
SOX Chemotherapy SOX Chemotherapy The First Affiliated Hospital with Nanjing Medical University marketed Combination chemotherapy regimen
CVP CVP SCRI Development Innovations, LLC marketed Combination chemotherapy regimen
chemotherapy of mFOLFOX6 or FOLFIRI chemotherapy of mFOLFOX6 or FOLFIRI Xu jianmin marketed Combination chemotherapy regimen Thymidylate synthase (5-FU), DNA topoisomerase I (irinotecan), DNA (oxaliplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy regimen class)

  1. Sun Yat-sen University · 5 drugs in this class
  2. Sixth Affiliated Hospital, Sun Yat-sen University · 2 drugs in this class
  3. Hoffmann-La Roche · 2 drugs in this class
  4. University Hospital, Bordeaux · 2 drugs in this class
  5. Beijing Friendship Hospital · 1 drug in this class
  6. Centre Hospitalier Universitaire Dijon · 1 drug in this class
  7. Amgen · 1 drug in this class
  8. Chungnam National University Hospital · 1 drug in this class
  9. AstraZeneca · 1 drug in this class
  10. Children's Cancer Group, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Arm B: FOLFIRI or FOLFOX — Competitive Intelligence Brief. https://druglandscape.com/ci/arm-b-folfiri-or-folfox. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: